top of page
TNA_HOME-01.jpg

TARGETING CANCER
AT THE ROOT

To develop best-in-class innovative molecules for patients

OUR MISSION

To develop best-in-class innovative molecules for patients 

We are developing best-in-class innovative molecules for patients battling rare and difficult to treat cancers with a high unmet medical need by targeting cancer at the root.

TNA_mission_molecule.jpg

OUR SCIENCES

We are leveraging our world leading expertise in cancer cell biology, molecular modelling and medicinal chemistry to identify and drug novel targets in oncology

BEST-IN-CLASS

Our small molecule inhibitors are being developed with the ultimate aim to provide significant patient benefit. By developing compounds that not only induce tumor regressions and synergize with existing standard of care but also have an impact on metastasis. 

TNA_Home_Science1-01.jpg
TNA_Home_Science-2-01.png

PREVENTION OF NEW MESTASTIC DISEASE

Existing therapeutic options typically only focus on primary tumor response and there remains a significant unmet need for agents that have an impact on established metastatic disease or the prevention of new metastatic disease

TARGETING CANCER STEM CELLS

By targeting Cancer Stem Cells, our lead development compound, TNAT-101, has the potential to not only treat primary disease but also prevent progression and recurrence leading to greater overall survival in patients. 

TNA_Home_Science3-02.png
TNA_HOME_About copy.jpg

ABOUT TNA THERAPEUTICS

Developing Potential
Treatments for a Variety
of Tumor Types

TNA Therapeutics Inc. is early stage pharmaceutical company focused on developing TNAT-101, a safe and well-tolerated first-in-class, oral agent that inhibits BCL3. By reducing and in most cases preventing further metastasis

TNA_HOME_History.jpg

OUR HISTORY

2

PATENTS

3

OFFICES

$14M

INVESTED

1.5kg

GMP DRUG MANUFACTURED

ABOUT TNA THERAPEUTICS

Partnering, Collaborating & Combining Towards the Future

TNA Therapeutics will grow through partnerships and collaborations

  • Grants received such as the Alderley Park/CRUK/InnovateUK award recently provided to the company

  • Partnership with Adlai Nortye in China to develop pelareorep for metastatic breast cancer

INNOVATE_UK_LOGO.png

INNOVATE UK

TNA_AP.png

ALDERLEY PARK

TNA_AN.png

ADLAI NORTYE

CRUK.png

CANCER RESEARCH

NEWS

Get the latest updates from TNA Therapeutics on new research, company news and upcoming events

TNA THERAPEUTICS ANNOUNCES 2022 PRIORITIES

Dr. Luke Piggott

We will continue to finalise the IND package to initiate clinical trials with our lead development candidate TNAT-101. We are also currently exploring the additional clinical opportunities to combine TNAT-101 with targeted and standard of care agents

bottom of page